Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
5 hedge funds and large institutions have $12.6K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
95% more capital invested
Capital invested by funds: $6.44K → $12.6K (+$6.14K)
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$39.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.32K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Signature Resources Capital Management
Newport Beach,
California
|
-$879 |
| 2 |
Wells Fargo
San Francisco,
California
|
-$34 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $10.3K | +$39.1K | +800 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1.63K | +$3.32K | +68 | +117% |
|
|
3
UBS Group
Zurich,
Switzerland
| $562 | +$2.1K | +43 | New |
|
|
SRCM
4
Signature Resources Capital Management
Newport Beach,
California
| $26 | -$879 | -18 | -90% |
|
5
Morgan Stanley
New York
| $8 | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $4 | – | – | – |
|
|
PA
7
Parallel Advisors
San Francisco,
California
| $1 | – | – | – |
|
|
8
Wells Fargo
San Francisco,
California
| – | -$34 | – | – |
|
VRPX Hedge Fund Activity: Q2 2024 in Review
5 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q2 2024, worth a combined $12.6K — up 95% from $6.44K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VRPX positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Warberg Asset Management, opening a new position worth an estimated $39.1K. The largest seller was Signature Resources Capital Management, cutting an estimated $879.
- 5 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q2 2024, up from 3 in Q1 2024.
- Funds reported $12.6K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q2 2024, up 95% quarter-over-quarter.
- 2 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 0 closed out, a net change of +2 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q2 2024 was Warberg Asset Management, an estimated $39.1K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was Signature Resources Capital Management, an estimated $879 sold.
Based on aggregated 13F filings for Q2 2024.